Milestones In Basket Trials: Novartis' Ambitious SIGNATURE Program

Novartis' tissue-agnostic SIGNATURE trial uses eight of the company's drugs in an ambitious set of Phase II protocols that will be an important test of whether basket trial designs are useful in corporate oncology R&D programs.